




OUTSOURCING

Key Trends in Offshoring Pharmaceutical R&D

Company strategies, emerging markets and impact on ROI

By Dr Cheryl L Barton

 **Table of Contents**

Dr Cheryl L Barton

Dr Cheryl L Barton is an independent consultant with over 16 years' research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer's disease to schizophrenia, Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst. At ABN Amro NV she was lead analyst on several pan-European companies, and assessed the potential impact of new drug development on European Stocks.

Copyright © 2009 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Key trends in offshoring pharmaceutical R&D: Company strategies, emerging markets and impact on ROI

| | |
|---|-----------|
| Executive summary | 10 |
| Offshoring: what, where & why? | 10 |
| Company analysis | 11 |
| Market analysis | 12 |
| Valuation | 13 |
| | |
| Chapter 1 Trends in offshoring R&D | 16 |
| Summary | 16 |
| Introduction | 17 |
| The evolution of offshoring | 17 |
| Trends in offshore locations | 19 |
| The decision to offshore | 21 |
| Offshoring vs inshoring | 23 |
| Emerging R&D trends | 25 |
| Conclusions | 28 |
| | |
| Chapter 2 Leading pharma and biotech offshore R&D strategies | 30 |
| Summary | 30 |
| Introduction | 31 |
| Leading pharma & biotech company revenues | 32 |
| Leading R&D portfolios | 34 |

| | |
|--|-----------|
| Global R&D footprint | 36 |
| Returns on investment in the emerging economies | 38 |
| The impact of economic crisis on pharma's cash position | 40 |
| Johnson & Johnson | 42 |
| Revenue | 42 |
| Emerging markets | 43 |
| Deals | 43 |
| Pfizer Inc | 45 |
| Acquisitions | 45 |
| R&D strategy | 46 |
| Deals | 48 |
| Roche Holdings Ltd | 49 |
| Acquisitions | 49 |
| R&D centers | 50 |
| R&D strategy | 50 |
| Offshore deals | 51 |
| Sanofi-Aventis | 52 |
| Offshore strategy | 52 |
| Offshore R&D facilities | 53 |
| Novartis AG | 54 |
| R&D strategy | 54 |
| Offshore activities | 55 |
| Deals | 56 |
| Offshore acquisitions | 58 |
| GlaxoSmithKline plc | 59 |
| R&D strategy | 60 |
| Outsourcing | 60 |
| Offshore R&D facilities & deals | 61 |
| AstraZeneca Plc | 62 |
| R&D facilities | 62 |
| Offshore deals | 64 |
| R&D strategy | 64 |
| Merck & Co Inc | 66 |
| Restructuring | 66 |
| New commercialization model | 66 |
| Offshore R&D strategy & deals | 67 |
| Eli Lilly & Co. | 68 |
| R&D strategy | 69 |
| Deals | 72 |
| Wyeth | 73 |
| R&D strategy | 73 |
| Clinical research partnerships | 74 |
| Bristol-Myers Squibb Company | 75 |
| BioPharma model | 76 |
| Strategic acquisitions | 77 |
| Amgen Inc | 78 |
| JVs and partnerships | 79 |
| Schering-Plough | 79 |
| R&D investment | 80 |
| Deals & acquisitions | 80 |

| | | |
|--------------------------|--------------------------------------|-----------|
| Abbott Labs | | 81 |
| Genentech | Deals | 82 |
| | | 83 |
| | R&D investment | 83 |
| | Acquisitions | 84 |
| Novo Nordisk A/S | | 85 |
| | Venture capital | 87 |
| Bayer Schering Pharma AG | | 87 |
| Biogen Idec | | 89 |
| | R&D evaluation | 89 |
| | Partnerships and strategic alliances | 90 |
| Baxter International | | 92 |
| Conclusions | | 94 |

Chapter 3 Offshoring hotspots and emerging markets players 98

| | | |
|--|-----------|------------|
| Summary | | 98 |
| Introduction | | 99 |
| Globalization | | 100 |
| Return on offshore R&D investment | | 102 |
| Regional offshore investment deals | | 103 |
| Asia-Pacific | | 104 |
| | China | 105 |
| | India | 106 |
| | Japan | 107 |
| | Singapore | 109 |
| Australia | | 110 |
| Eastern Europe | | 112 |
| Latin America | | 113 |
| | Brazil | 115 |
| Middle East | | 116 |
| | Israel | 116 |
| South Africa | | 118 |
| Conclusions | | 119 |

Chapter 4 ROI from offshoring R&D 122

| | | |
|---|--|------------|
| Summary | | 122 |
| Introduction | | 123 |
| Key areas for return on investment | | 123 |
| R&D valuation | | 128 |

| | |
|-------------------------------|------------|
| Financial performance | 130 |
| Managerial performance | 132 |
| Conclusions | 136 |
| Index | 138 |

List of Figures

| | | |
|--------------|---|-----|
| Figure 1.1: | Areas for R&D offshoring | 18 |
| Figure 1.2: | Primary, secondary & tertiary investment | 20 |
| Figure 1.3: | Key drivers for offshore investment | 22 |
| Figure 1.4: | Balancing local and offshore investments | 24 |
| Figure 1.5: | Trends in R&D | 25 |
| Figure 2.6: | Pharma/biotech R&D intensity (%), 2007 | 33 |
| Figure 2.7: | Leading pharma mid-to-late-stage product pipelines (no. of late stage pipeline products), 2007 | 34 |
| Figure 2.8: | Leading pharma replacement power, 2007 | 35 |
| Figure 2.9: | Healthcare global R&D footprint | 36 |
| Figure 2.10: | Accelerated growth in the Emerging Markets, 2006 | 38 |
| Figure 2.11: | Geographic diversification of leading pharma sales, July 2007-Jun 2008 | 39 |
| Figure 2.12: | J&J pharma sales (% share by product), 2007 | 42 |
| Figure 2.13: | J&J deals by type (no. deals), 2007 | 44 |
| Figure 2.14: | Origin of material of drugs by Roche, Genentech & Chugai, 2007 | 51 |
| Figure 2.15: | Novartis Pharma sales, 2007 | 54 |
| Figure 2.16: | Novartis deals, 2007 | 57 |
| Figure 2.17: | Merck's commercialization model, Dec 2007 | 67 |
| Figure 2.18: | Eli Lilly deals by type (no. deals), 2007 | 71 |
| Figure 2.19: | BMS biopharma model 2008 | 76 |
| Figure 2.20: | Schering-Plough deals by type (no. deals), 2007 | 81 |
| Figure 2.21: | Novo Nordisk's R&D strategy, 2008 | 85 |
| Figure 2.22: | Biogen's shareholder value creation plan | 90 |
| Figure 2.23: | Baxter's global sales by region, 2007 | 92 |
| Figure 3.24: | Global R&D performance payoff for leading R&D spenders, 2005-2007 | 103 |
| Figure 3.25: | Location of offshore contract R&D (number of deals), 2004-2008 | 104 |
| Figure 3.26: | China offshore activity (% deals), 2004-2008 | 105 |
| Figure 3.27: | India offshore activity (% deals), 2004-2008 | 106 |
| Figure 3.28: | Japan offshore R&D activity (% deals), 2004-2008 | 107 |
| Figure 3.29: | Singapore offshore activity (% deals), 2004-2008 | 109 |
| Figure 3.30: | Australian offshore activity (% deals), 2004-2008 | 111 |
| Figure 3.31: | Eastern Europe offshore activity (% deals),2004-2008 | 112 |
| Figure 3.32: | Brazil offshore activity (% deals), 2004-2008 | 115 |
| Figure 3.33: | Israel offshore activity (% deals), 2004-2008 | 117 |
| Figure 3.34: | South Africa offshore activity (% deals), 2004-2008 | 118 |
| Figure 4.35: | Pharmaceutical R&D expenditure, average R&D expenditure per NAS launch, average ROI per NAS (1988-2000) | 124 |
| Figure 4.36: | New strategic and decision making models to target productivity issues | 125 |
| Figure 4.37: | US pharmaceutical P/E ratios | 130 |
| Figure 4.38: | US biotechnology P/E ratios | 131 |
| Figure 4.39: | Leading companies over-performed ROA showed positive 5 year growth | 132 |

| | | |
|--------------|--|-----|
| Figure 4.40: | Leading companies over-performed ROA showed negative 5 year growth | 133 |
| Figure 4.41: | Leading companies over-performed ROI showed positive 5 year growth | 134 |
| Figure 4.42: | Leading companies over-performed ROI showed negative 5 year growth | 135 |

List of Tables

| | | |
|-------------|---|-----|
| Table 1.1: | Global technology research parks in secondary & tertiary countries | 27 |
| Table 2.2: | Top 20 pharma/biotech revenues & R&D investment (\$m), 2007 | 32 |
| Table 2.3: | J&J emerging economy sales growth (%), Q308 | 43 |
| Table 2.4: | J&Js recent R&D activities (ex US and top 5 European countries) | 45 |
| Table 2.5: | Pfizer's recent R&D activities (outside the leading pharma countries) | 48 |
| Table 2.6: | Roche's recent R&D activities (outside the leading pharma countries) | 52 |
| Table 2.7: | Sanofi Aventis recent R&D activities (outside the leading pharma countries) | 53 |
| Table 2.8: | Novartis AG recent R&D activities (outside the leading pharma countries) | 58 |
| Table 2.9: | GlaxoSmithKline recent R&D activities (outside the leading pharma countries) | 59 |
| Table 2.10: | AstraZeneca recent R&D activities (outside the leading pharma countries) | 63 |
| Table 2.11: | Merck & Co recent R&D activities (outside the leading pharma countries) | 68 |
| Table 2.12: | Eli Lilly recent R&D activities (outside the leading pharma countries) | 72 |
| Table 2.13: | Wyeth's recent R&D activities (outside the leading pharma countries) | 74 |
| Table 2.14: | Amgen recent R&D activities (outside the leading pharma countries) | 79 |
| Table 2.15: | Abbott's recent R&D activities (outside the leading pharma countries) | 82 |
| Table 2.16: | Genentech recent R&D activities (outside the leading pharma countries) | 84 |
| Table 2.17: | Novo Nordisk's recent R&D activities (outside the leading pharma countries) | 86 |
| Table 2.18: | Bayer Schering's recent R&D activities (outside the leading pharma countries) | 88 |
| Table 2.19: | Biogen Idec recent R&D activities (outside the leading pharma countries) | 91 |
| Table 2.20: | Baxter's worldwide facilities, 2008 | 93 |
| Table 3.21: | Top Ten R&D generators, users and importers (US\$bn), 2007 | 100 |
| Table 3.22: | Latin American offshore agreements | 114 |
| Table 4.23: | R&D productivity high and low benchmarks | 126 |
| Table 4.24: | Valuation ratios by company | 129 |
| Table 4.25: | Industry investment summary | 137 |